相关实验视频

Updated: Sep 13, 2025

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

circEFR3A通过海绵miR-590-3p促进乳腺癌的进展,以调节雄激素受体表达的表达

Yunzhe Mi¹, Xinle Wang¹, Han Song²

¹Breast Center, The Fourth Hospital of Hebei Medical University, Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China.

Oncology letters

|July 31, 2025

概括

循环RNA hsa_circ_0006522 (circEFR3A) 在乳腺癌 (BC) 中被上调,促进瘤进展和不良预后. CircEFR3A通过海绵化miR-590-3p作为瘤基因,增加雄激素受体 (AR) 表达.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学遗传学是一个

背景情况:

循环RNA (circRNAs) 是关键的非编码RNA,涉及各种疾病,包括癌症.
异常的circRNA表达越来越被认为是瘤发生和进展的驱动因素.
乳腺癌 (BC) 发病过程涉及复杂的分子机制,需要识别新的调节因素.

研究的目的:

研究hsa_circ_0006522 (circEFR3A) 在乳腺癌 (BC) 进展中的作用.
阐明 circEFR3A 在BC中的功能背后的分子机制.
在BC患者中评估circEFR3A的预后价值.

主要方法:

光在位混合化 (FISH) 用于表达和定位.
卡普兰-梅尔分析和考克斯的比例危险模型用于预后评估.
功能获取和丧失实验,双露西法酶记者测定,RNA免疫沉和西部涂抹以确定分子相互作用.

主要成果:

在BC组织中,CircEFR3A显著上调,与患者预后不佳相关.
增加circEFR3A表达促进了BC细胞的增殖,入侵,迁移,以及体内瘤的生长.
CircEFR3A作为miR-590-3p的分子海绵,调节上升受体 (AR) 表达,并作为瘤基因.

结论:

在乳腺癌 (BC) 中,CircEFR3A 作为一种新瘤基因.
在circEFR3A/miR-590-3p/AR轴驱动BC的进展.
CircEFR3A可以作为潜在的预后生物标志物和BC的治疗点.

关键词:

受体受体是受体的受体.乳腺癌乳腺癌乳腺癌这就是circEFR3A.这种微型RNA-590-3p.

更多相关视频

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

相关概念视频

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...